

Thomas Prebet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5684798/publications.pdf>

Version: 2024-02-01

189
papers

6,745
citations

81434

41
h-index

81351

76
g-index

191
all docs

191
docs citations

191
times ranked

8947
citing authors

#	ARTICLE	IF	CITATIONS
1	In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2. <i>Leukemia</i> , 2022, 36, 1313-1323.	3.3	11
2	A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, , 1-9.	0.6	2
3	High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis. <i>Leukemia and Lymphoma</i> , 2021, 62, 1195-1202.	0.6	5
4	Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 994-1002.	2.5	18
5	Current challenges and unmet medical needs in myelodysplastic syndromes. <i>Leukemia</i> , 2021, 35, 2182-2198.	3.3	46
6	A phase 1 study of the pan- α -bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 2943-2953.	2.0	42
7	Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2021, 62, 3394-3401.	0.6	17
8	Comprehensive Clinicopathologic and Molecular Analysis of Mast Cell Leukemia With Associated Hematologic Neoplasm: A Report and In-Depth Study of 5 Cases. <i>Frontiers in Oncology</i> , 2021, 11, 730503.	1.3	2
9	Impact of an automatic palliative care consultation trigger on healthcare use in patients with relapsed/refractory acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2021, 39, 224-224.	0.8	1
10	NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 16-27.	2.3	170
11	Implementation of Inpatient Palliative Care Consultation Triggers and Its Impact on Healthcare Use in Patients with Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 3018-3018.	0.6	1
12	Hypomethylating agent based combinations in higher risk myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 2020, 61, 1012-1027.	0.6	2
13	Emerging treatment options for patients with high-risk myelodysplastic syndrome. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072095500.	1.1	19
14	Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. <i>Blood Advances</i> , 2020, 4, 2866-2870.	2.5	81
15	Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia. <i>Leukemia Research</i> , 2020, 91, 106339.	0.4	20
16	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with <i>FLT3</i> -internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1507-1516.	1.7	91
17	Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 246-249.	0.6	0
18	Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid disease. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 930-934.	0.7	5

#	ARTICLE	IF	CITATIONS
19	Insights into novel emerging epigenetic drugs in myeloid malignancies. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071986608.	1.1	6
20	What are the most promising new agents in myelodysplastic syndromes?. <i>Current Opinion in Hematology</i> , 2019, 26, 77-87.	1.2	2
21	Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. <i>Blood Advances</i> , 2019, 3, 1540-1545.	2.5	44
22	Results from the first-in-human study of mivebresib (ABBV-075), a pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7030-7030.	0.8	14
23	Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 721-749.	2.3	314
24	Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1754-1758.	2.0	6
25	Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. <i>Lancet Haematology</i> , 2018, 5, e63-e72.	2.2	95
26	Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase 3 randomised controlled trial. <i>British Journal of Haematology</i> , 2018, 180, 735-737.	1.2	10
27	The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. <i>Blood Advances</i> , 2018, 2, 1765-1772.	2.5	100
28	Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 2063-2071.	2.5	26
29	Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. <i>Blood Advances</i> , 2018, 2, 923-932.	2.5	114
30	Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities. <i>Frontiers in Immunology</i> , 2018, 9, 977.	2.2	25
31	NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents. <i>Haematologica</i> , 2018, 103, e455-e457.	1.7	22
32	Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2018, 59, 755-757.	0.6	6
33	FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): Results from a Phase 1 Study. <i>Blood</i> , 2018, 132, 1452-1452.	0.6	16
34	Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018, 132, 1453-1453.	0.6	11
35	A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7009-7009.	0.8	19
36	Prognostic understanding in acute leukemia: Patient-physician differences.. <i>Journal of Clinical Oncology</i> , 2018, 36, e22124-e22124.	0.8	2

#	ARTICLE	IF	CITATIONS
37	Acquired TET 2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T2-ALL and AML -M0. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 1237-1242.	1.6	10
38	Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1880-1886.	0.6	14
39	Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the <i>Groupe Francophone Des My�lodysplasies</i>. <i>Haematologica</i> , 2017, 102, 728-735.	1.7	22
40	Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine. <i>Leukemia Research</i> , 2017, 63, 72-77.	0.4	14
41	Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1213-1224.	0.9	13
42	Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. <i>Leukemia and Lymphoma</i> , 2017, 58, 982-985.	0.6	16
43	Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings. <i>Leukemia and Lymphoma</i> , 2017, 58, 1022-1036.	0.6	53
44	Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. <i>Transfusion</i> , 2017, 57, 289-295.	0.8	19
45	Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care. <i>Blood Cancer Journal</i> , 2017, 7, 644.	2.8	15
46	Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. <i>International Journal of Molecular Sciences</i> , 2017, 18, 837.	1.8	19
47	Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy. <i>Oncotarget</i> , 2017, 8, 37866-37874.	0.8	10
48	Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy. <i>Oncotarget</i> , 2017, 8, 81926-81935.	0.8	15
49	Clinical Applications of Epigenetic Drugs. , 2016, , 329-346.		0
50	An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 51163-51173.	0.8	15
51	Chronic myelomonocytic leukemia: Are we finally solving the identity crisis?. <i>Blood Reviews</i> , 2016, 30, 381-388.	2.8	3
52	Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system. <i>Haematologica</i> , 2016, 101, e427-e428.	1.7	13
53	A randomized phase II trial of azacitidine +/- epoetin-� in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents. <i>Haematologica</i> , 2016, 101, 918-925.	1.7	55
54	Trends in Clinical Investigation for Myelodysplastic Syndromes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S57-S63.	0.2	11

#	ARTICLE	IF	CITATIONS
55	Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2016, 175, 829-840.	1.2	59
56	Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy. <i>Blood</i> , 2016, 128, 253-264.	0.6	320
57	Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2016, 95, 1895-1898.	0.8	2
58	Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. <i>British Journal of Haematology</i> , 2016, 172, 384-391.	1.2	63
59	Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 307-317.	1.9	45
60	Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients. <i>Cancer Research</i> , 2016, 76, 2082-2086.	0.4	24
61	New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities. <i>Expert Review of Hematology</i> , 2016, 9, 377-388.	1.0	16
62	The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort. <i>Blood</i> , 2016, 128, 1063-1063.	0.6	5
63	Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD). <i>Blood</i> , 2016, 128, 215-215.	0.6	25
64	Epigenetics in Cancer: A Hematological Perspective. <i>PLoS Genetics</i> , 2016, 12, e1006193.	1.5	77
65	Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies. <i>Oncotarget</i> , 2016, 7, 85937-85947.	0.8	9
66	Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 32532-32542.	0.8	75
67	Evaluation of Salvage Induction Chemotherapy Regimens in Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment Failure. <i>Blood</i> , 2016, 128, 348-348.	0.6	0
68	Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy. Prospective Observational Study from the Acute Leukemia French Association (ALFA) Group. <i>Blood</i> , 2016, 128, 3696-3696.	0.6	1
69	Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis. <i>American Journal of Hematology</i> , 2015, 90, 737-738.	2.0	15
70	Overexpression of the Promigratory and Prometastatic PTK7 Receptor Is Associated with an Adverse Clinical Outcome in Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0123768.	1.1	43
71	Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2015, 5, e292-e292.	2.8	21
72	Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 766-770.e4.	0.2	13

#	ARTICLE	IF	CITATIONS
73	PcG methylation of the HIST1 cluster defines an epigenetic marker of acute myeloid leukemia. <i>Leukemia</i> , 2015, 29, 1202-1206.	3.3	8
74	Development of Epigenetic Targeted Therapies in Hematological Malignancies. , 2015, , 169-187.		2
75	Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. <i>Haematologica</i> , 2015, 100, 780-785.	1.7	42
76	Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities. <i>American Journal of Hematology</i> , 2015, 90, 859-863.	2.0	17
77	Comparison of 60 or 90 mg/m ² of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics. <i>American Journal of Hematology</i> , 2015, 90, E29-30.	2.0	19
78	Azacitidine for the treatment of relapsed and refractory AML in older patients. <i>Leukemia Research</i> , 2015, 39, 124-130.	0.4	63
79	Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patients. <i>American Journal of Hematology</i> , 2015, 90, E22-4.	2.0	16
80	Outcome of Patients Treated for Myelodysplastic Syndromes after Failure of Lenalidomide Therapy. <i>Blood</i> , 2015, 126, 95-95.	0.6	3
81	A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL).. <i>Journal of Clinical Oncology</i> , 2015, 33, 3065-3065.	0.8	21
82	Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes. <i>Oncotarget</i> , 2015, 6, 8388-8396.	0.8	69
83	The PTK7 Receptor Family. , 2015, , 539-558.		1
84	French consensus on myelodysplastic syndrome and chronic myelomonocytic leukemia: diagnostic, classification and treatment 2015 update by the Myelodysplasia French Group. <i>Hematologie</i> , 2015, 21, 28-45.	0.0	1
85	Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS). <i>Blood</i> , 2015, 126, 3285-3285.	0.6	1
86	North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia. <i>Blood</i> , 2015, 126, 1138-1138.	0.6	4
87	Patterns of Venous Thromboembolism Prophylaxis during Inpatient Treatment of Acute Leukemia: Results of a North American Web-Based Survey. <i>Blood</i> , 2015, 126, 4455-4455.	0.6	0
88	A Phase II Add-on Study of Vorinostat (VOR) in Higher Risk Myelodysplastic Syndrome with Failure of Hypomethylating Agents (HMA): The GFM Azavor Study. <i>Blood</i> , 2015, 126, 2900-2900.	0.6	1
89	Clinical Evaluation of Combined Epigenetic Therapies on the Induction of Fetal Hemoglobin in Patients with Hematologic Malignancies. <i>Blood</i> , 2015, 126, 960-960.	0.6	0
90	Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. <i>Leukemia Research</i> , 2014, 38, 1381-1391.	0.4	27

#	ARTICLE	IF	CITATIONS
91	Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. <i>Blood</i> , 2014, 124, 1312-1319.	0.6	61
92	Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity. <i>Frontiers in Immunology</i> , 2014, 5, 122.	2.2	75
93	Evaluation of comorbidity indexes in the outcome of elderly patients treated for acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 2211-2212.	0.6	7
94	Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?. <i>Expert Review of Hematology</i> , 2014, 7, 191-194.	1.0	6
95	Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2014, 166, 352-359.	1.2	31
96	Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2014, 38, 29-33.	0.4	16
97	Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2014, 89, 604-609.	2.0	36
98	A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure. <i>Leukemia Research</i> , 2014, 38, 1430-1434.	0.4	16
99	Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. <i>British Journal of Haematology</i> , 2014, 167, 62-68.	1.2	27
100	Poor Outcome with Nonmyeloablative Conditioning Regimen before Cord Blood Transplantation for Patients with High-Risk Acute Myeloid Leukemia Compared with Matched Related or Unrelated Donor Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1560-1565.	2.0	11
101	Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905. <i>Journal of Clinical Oncology</i> , 2014, 32, 1242-1248.	0.8	227
102	Planctomycetes DNA in Febrile Aplastic Patients with Leukemia, Rash, Diarrhea, and Micronodular Pneumonia. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3453-3455.	1.8	20
103	Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia. <i>Haematologica</i> , 2014, 99, e185-e187.	1.7	27
104	An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion. <i>Blood</i> , 2014, 124, 3251-3251.	0.6	23
105	Preventive Versus Curative Platelet Transfusion Strategies in the Treatment of Acute Myeloid Leukemia Patients: A Comparative Study. <i>Blood</i> , 2014, 124, 4288-4288.	0.6	1
106	Therapeutic Targeting of c-Myc in T-Cell Acute Lymphoblastic Leukemia (T-ALL). <i>Oncotarget</i> , 2014, 5, 3168-3172.	0.8	58
107	H3K27me3 Level of the HIST1 Cluster Defines an Epigenetic Marker of Acute Myeloid Leukemia with Prognostic Value. <i>Blood</i> , 2014, 124, 2326-2326.	0.6	0
108	Incidence of Atrx Mutations in Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2014, 124, 4629-4629.	0.6	0

#	ARTICLE	IF	CITATIONS
109	A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse. <i>Leukemia</i> , 2013, 27, 1479-1486.	3.3	50
110	Impact of Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation on Women's Fertility. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 704-710.	0.2	24
111	Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1228-1234.	0.6	43
112	5-azacitidine in the treatment of myelodysplastic syndrome and acute myeloid leukemia. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 419-428.	0.7	1
113	Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. <i>Leukemia and Lymphoma</i> , 2013, 54, 1538-1540.	0.6	12
114	Concomitant germline <i>RUNX1</i> and acquired <i>ASXL1</i> mutations in a T-cell acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2013, 91, 277-279.	1.1	25
115	BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. <i>Blood</i> , 2013, 122, 3169-3177.	0.6	169
116	Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?. <i>Blood</i> , 2013, 122, 2286-2288.	0.6	67
117	Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure. <i>Haematologica</i> , 2013, 98, e18-e19.	1.7	29
118	Azacitidine Treatment For Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia Harboring Chromosome 3q Abnormalities. <i>Blood</i> , 2013, 122, 1512-1512.	0.6	1
119	Impact Of Anthracycline Dose Intensification On Minimal Residual Disease and Outcome Of Core Binding Factors Acute Myeloid Leukemias. <i>Blood</i> , 2013, 122, 2681-2681.	0.6	1
120	Repeated Dosing Of Anti-KIR (IPH2101) As Maintenance Therapy In Ederly Patients With Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 2696-2696.	0.6	7
121	Impact Of Cytogenetics and Cytogenetic Response On Outcome In Myelodysplastic Syndromes (MDS) treated With Azacitidine (AZA). A Collaborative Study In 878 Patients. <i>Blood</i> , 2013, 122, 389-389.	0.6	6
122	Lenalidomide (LEN) Combined To Intensive Chemotherapy (IC) In AML and Higher Risk MDS With Del 5q. Results Of a Phase I/II Study Of The Groupe Francophone Des Myelodysplasies (GFM). <i>Blood</i> , 2013, 122, 620-620.	0.6	2
123	Prognostic Factors Of Response and Survival To Azacitidine (AZA) +/- EPO In RBC Transfusion Dependent (TD) IPSS Low and Int-1 (LR) MDS Resistant To EPO, With Particular Emphasis Of Genetic Lesions: A Study By The GFM. <i>Blood</i> , 2013, 122, 658-658.	0.6	1
124	The Revised IPSS (IPSS-R) Predicts Response To Erythropoietic Stimulating agents (ESA) In Pts With Classical IPSS Low Or Intermediate-1 (int 1)- MDS: A Joint Retrospective Study Of The GFM, Düsseldorf and Fism. <i>Blood</i> , 2013, 122, 2761-2761.	0.6	1
125	Azacitidine With Or Without Entinostat For The Treatment Of Therapy-Related Myeloid Neoplasm: Further Results Of The E1905 North American Leukemia Intergroup Study. <i>Blood</i> , 2013, 122, 2777-2777.	0.6	5
126	Reduced Intensity Conditioning Based On Fludarabine, Intravenous Busulfan (2 Days) and Antithymocyte Globulins (2 Days) Results In High Disease Free Survival Without Persisting Gvhd In Patients Transplanted For Hematological Malignancies: Large Single Center Cohort With Long Follow-Up. <i>Blood</i> , 2013, 122, 3364-3364.	0.6	0

#	ARTICLE	IF	CITATIONS
127	The increase from 2.5 to 5â€‰%mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone Marrow Transplantation, 2012, 47, 639-645.	1.3	73
128	Extensive chronic GVHD is associated with donor blood CD34+ cell count after G-CSF mobilization in non-myeloablative allogeneic PBSC transplantation. Bone Marrow Transplantation, 2012, 47, 1564-1568.	1.3	9
129	Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction. Leukemia and Lymphoma, 2012, 53, 2186-2191.	0.6	7
130	Phase I and pharmacokinetic study of elacytarabine, a novel 5â€‰ ² -elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies. Leukemia, 2012, 26, 1686-1689.	3.3	18
131	A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood, 2012, 120, 4317-4323.	0.6	247
132	Incidence of 17p deletions and <i>TP53</i> mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Genes Chromosomes and Cancer, 2012, 51, 1086-1092.	1.5	67
133	PICALMâ€‰“MLLT10 acute myeloid leukemia: A French cohort of 18 patients. Leukemia Research, 2012, 36, 1365-1369.	0.4	36
134	Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1. Leukemia, 2012, 26, 662-674.	3.3	72
135	Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood, 2012, 119, 3211-3218.	0.6	220
136	Lenalidomide in lowerâ€‰risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesisâ€‰stimulating agents. British Journal of Haematology, 2012, 156, 619-625.	1.2	32
137	Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure. British Journal of Haematology, 2012, 157, 764-766.	1.2	49
138	Design of N-substituted Amino Caproic Hydroxamic Acid Histone Deacetylase Inhibitors Reveal an Essential Role for Cap Atomic Composition. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 801-806.	0.9	0
139	The Addition of ONE-Day Rest Between LAST ATG Infusion and STEM CELL Infusion DID NOT Affect Gvhd Occurrence After Allogeneic TRANSPLANTATION with Fludarabine-Busulfan-ATG Conditioning.. Blood, 2012, 120, 3029-3029.	0.6	0
140	BCOR Mutations Represent an Independent Factor of Poor Prognosis in Myelodysplastic Syndromes. Blood, 2012, 120, 1697-1697.	0.6	0
141	A phase I /II Trial of Erlotinib in Higher Risk MDS After Azacitidine (AZA) Failure. Blood, 2012, 120, 1719-1719.	0.6	0
142	Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Expert Opinion on Investigational Drugs, 2011, 20, 287-295.	1.9	35
143	Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia. Blood, 2011, 117, 6650-6659.	0.6	72
144	Treatment of Acute Promyelocytic Leukemia for Older Patients. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 337-342.	2.3	2

#	ARTICLE	IF	CITATIONS
145	Protein tyrosine kinase 7 has a conserved role in Wnt/ β -catenin canonical signalling. <i>EMBO Reports</i> , 2011, 12, 43-49.	2.0	93
146	A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogenous leukaemia patients: a GOELAMS study. <i>Leukemia</i> , 2011, 25, 939-944.	3.3	101
147	Improved outcome of patients with low and intermediate risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine. <i>Cancer</i> , 2011, 117, 974-981.	2.0	19
148	Pegylated IFN- α 2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone. <i>Leukemia Research</i> , 2011, 35, 80-86.	0.4	16
149	Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure. <i>Journal of Clinical Oncology</i> , 2011, 29, 3322-3327.	0.8	421
150	PTK7: A cell polarity receptor with multiple facets. <i>Cell Cycle</i> , 2011, 10, 1233-1236.	1.3	32
151	Natural Killer Cells Recovery After Consolidation Chemotherapy in Elderly Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2011, 118, 2189-2189.	0.6	4
152	Low-Dose Clofarabine Has Significant Activity in High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia Post-MDS (sAML) After Azacitidine (AZA) Failure: Interim Results of the GFM Clo08 Dose Escalating Phase I/II Study (NCT0106325). <i>Blood</i> , 2011, 118, 609-609.	0.6	8
153	RAD001: A Clinico-Biological Phase I GOELAMS trial of Everolimus Association with High Dose Chemotherapy in Late Relapsing AML Patients Under 65 Years of Age. <i>Blood</i> , 2011, 118, 945-945.	0.6	0
154	Combination of Cytarabine and Topotecan Improves Response Rate for Patients Treated for Acute Myeloid Leukemia with Persistent Disease After Frontline Induction. <i>Blood</i> , 2011, 118, 2605-2605.	0.6	0
155	Fertility in Female Patients After Allogeneic Stem Cell Transplantation Following Reduced-Intensity Conditioning (RIC allo-SCT). <i>Blood</i> , 2011, 118, 3057-3057.	0.6	0
156	Use of Clofarabine in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Adults: The French Experience. <i>Blood</i> , 2011, 118, 2623-2623.	0.6	0
157	Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies. <i>Haematologica</i> , 2010, 95, 892-899.	1.7	18
158	Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantation. <i>Experimental Hematology</i> , 2010, 38, 55-60.	0.2	16
159	Reduced-intensity conditioning with Fludarabine, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies. <i>Experimental Hematology</i> , 2010, 38, 1241-1250.	0.2	36
160	Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin. <i>Leukemia</i> , 2010, 24, 467-469.	3.3	29
161	FES kinases are required for oncogenic FLT3 signaling. <i>Leukemia</i> , 2010, 24, 721-728.	3.3	28
162	Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2010, 45, 165-170.	1.3	24

#	ARTICLE	IF	CITATIONS
163	Tumor cell contamination in ovarian tissue cryopreserved before gonadotoxic treatment: should we systematically exclude ovarian autograft in a cancer survivor?. Bone Marrow Transplantation, 2010, 45, 1247-1248.	1.3	21
164	Allogeneic hematopoietic SCT and mechanical heart valve: feasibility of reduced toxicity myeloablative conditioning. Bone Marrow Transplantation, 2010, 45, 1574-1575.	1.3	2
165	The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome. Blood, 2010, 116, 2315-2323.	0.6	79
166	Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/âˆ™ Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone. Blood, 2010, 116, 1880-1880.	0.6	6
167	A 10 Day Schedule of Azacitidine Induces More Complete Cytogenetic Remissions Than the Standard Schedule In Myelodysplasia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the E1905 US Leukemia Intergroup Study. Blood, 2010, 116, 4013-4013.	0.6	5
168	Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) In AML and Higher Risk MDS with Del 5q. Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies (GFM). Blood, 2010, 116, 508-508.	0.6	7
169	Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905. Blood, 2010, 116, 601-601.	0.6	9
170	Lenalidomide (LEN) In Lower-Risk Myelodysplastic Syndromes (MDS) with Karyotypes Other Than Deletion 5q and Refractory to Erythropoiesis-Stimulating Agents (ESAs). Blood, 2010, 116, 4002-4002.	0.6	0
171	A Phase I-II Study of Vorinostat and Low Dose Cytarabine for Patients Treated for High Risk Myelodysplastic with Azacytidine Failure: The GFM-VOR2007 Study. Blood, 2010, 116, 4003-4003.	0.6	2
172	Post-Transcriptional Deregulation of MYC Via PTEN Constitutes a Major Alternative Pathway of MYC Activation In T-Cell Acute Lymphoblastic Leukemia. Blood, 2010, 116, 4188-4188.	0.6	0
173	A simplified, 96-wellâ€“adapted, ATP luminescenceâ€“based motility assay. BioTechniques, 2009, 47, 871-875.	0.8	4
174	Acute Myeloid Leukemia With Translocation (8;21) or Inversion (16) in Elderly Patients Treated With Conventional Chemotherapy: A Collaborative Study of the French CBF-AML Intergroup. Journal of Clinical Oncology, 2009, 27, 4747-4753.	0.8	123
175	P111 Long-term outcome of MDS with del 5q before the lenalidomide era. The GFM experience. Leukemia Research, 2009, 33, S124.	0.4	0
176	Mutations of polycombâ€“associated gene <i>ASXL1</i> in myelodysplastic syndromes and chronic myelomonocytic leukaemia. British Journal of Haematology, 2009, 145, 788-800.	1.2	537
177	Presence of a minor Philadelphia-positive clone in young adults with de novo T-cell ALL. Leukemia and Lymphoma, 2009, 50, 485-487.	0.6	9
178	Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood, 2009, 113, 3947-3952.	0.6	158
179	Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) in AML and Higher Risk MDS with Del 5q. Interim Results of a Phase I/II Study.. Blood, 2009, 114, 1049-1049.	0.6	4
180	Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110â€“FGFR1 fusion: Report of a new case and review of the literature. Leukemia Research, 2008, 32, 1304-1308.	0.4	24

#	ARTICLE	IF	CITATIONS
181	Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Soci�t� Fran�saise de Greffe de Moelle et de Th�rapie Cellulaire. <i>Experimental Hematology</i> , 2008, 36, 535-544.	0.2	58
182	High Relapse Rate of Acute Myeloid Leukemia with Translocation (8;21) or Inversion (16) in Elderly Patients Treated with Conventional Chemotherapy.. <i>Blood</i> , 2007, 110, 4365-4365.	0.6	2
183	Impact of CRi on the Outcome of Elderly Patients with Acute Myeloid Leukemia.. <i>Blood</i> , 2007, 110, 4384-4384.	0.6	1
184	A Phase I Study with CP-4055 In Patients with Hematologic Malignancies.. <i>Blood</i> , 2007, 110, 901-901.	0.6	0
185	Anti-Acute Myeloid Leukemia Activity of Chaetocin, a Novel Epigenetic Drug Inhibitor Inducing Oxidative Stress.. <i>Blood</i> , 2007, 110, 889-889.	0.6	1
186	Autologous hematopoietic stem cell transplantation for adults with acute myeloid leukemia in complete remission: The Edouard Herriot hospital experience. <i>Hematology</i> , 2006, 11, 157-164.	0.7	3
187	Treatment of High Risk MDS and AML Post-MDS with Azacytidine (AZA): Preliminary Results of the French ATU Program.. <i>Blood</i> , 2006, 108, 2664-2664.	0.6	4
188	Secondary Philadelphia chromosome after non-myeloablative peripheral blood stem cell transplantation for a myelodysplastic syndrome in transformation. <i>Bone Marrow Transplantation</i> , 2004, 33, 247-249.	1.3	7
189	A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes. <i>The Hematology Journal</i> , 2004, 5, 209-215.	2.0	7